29 maj: Solkystens luksuriøse oase – Marbella Club
31 maj: Skattereform: Ny kapitalpension er generationsrøveri til 150 mia...
29-05-2012 22:39:00

UPDATE: J&J Unit Gets FDA Warning Letter On K-Y Vaginal Moisturizer

Relateret indhold

(Updates with McNeil statement starting in the third paragraph.)

--FDA warns J&J unit on failure to properly investigate some consumer complaints

--Most of the letter details problems related to K-Y vaginal moisturizer

--FDA says a reporting problem related to O.B. Tampons has been adequately addressed

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration said a Johnson & Johnson (JNJ) unit didn't properly investigate consumer complaints related to a vaginal moisturizer.

The agency, in a warning letter dated May 22, said the company received more than 200 complaints about K-Y liquibeads vaginal moisturizer, which is made by McNeil PPC Inc., from June 25, 2010, through Dec. 12, 2011. The agency said the complaints included reports of the product not dissolving or having an uncharacteristic consistency or texture. FDA said some of the complaints were closed without being investigated by the company. McNeil also didn't adequately investigate some complaints that contained an incorrect lot number, according to FDA.

In a statement, McNeil said it takes the issues raised by FDA seriously. "We will respond fully to their concerns and take whatever steps are needed to resolve these issues," the company said.

The warning letter was posted to the FDA's website on Tuesday. The letter stems from an inspection conducted by the FDA of a McNeil facility in Skillman, N.J. on Dec. 12, 2011 through Jan. 19, 2012.

The FDA also said the company was late in submitting a report about a person being diagnosed with toxic shock syndrome after using an O.B. Tampon, also made by McNeil. However, the FDA said the company had adequately responded to the agency's concerns about that report.

Johnson & Johnson's McNeil Consumer Healthcare unit has been working to address manufacturing problems that led to recalls of Tylenol and other over-the-counter products starting in 2009. Three of the company's manufacturing plants were placed under an FDA consent decree last year and one of the plants, in Fort Washington, Pa., is still shut down.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

(END) Dow Jones Newswires

May 29, 2012 16:39 ET (20:39 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Moody's forudser indtjeningsvækst på 4-5 pct. i shippingmarkedet

18-06-2018 15:54:48
Udsigterne for det globale shippingmarked ser stabile ud for det næste års tid, vurderer kreditvurderingsinstituttet Moody's, som dog også spår forskelle i de enkelte undersegmenter. For tørlastsegmentet venter Moody's, at efterspørgslen vil overgå udbuddet med 1 pct. i 2018, mens der for containermarkedet ses en efterspørgsel, som vil være understøttet af bred makroøkonomisk vækst og handelsvækst..

Vestas-formand efter TDC-entre: Har ingen planer om at forlade Vestas

18-06-2018 12:00:37
Vestas' bestyrelsesformand siden 2012, Bert Nordberg, har ingen planer om at forlade den danske vindmølleproducent for at gøre plads til den formandspost hos TDC, som svenskeren tiltræder 1. august. Han erkender i et interview med Ritzau Finans dog, at det kan blive nødvendigt at skære ned på sine bestyrelsesposter. - Jeg overvejer det, men det er en drøftelse, jeg tager med nomineringskomitéerne ..

NKT/ABG: Falmende franske forventninger sender aktien ned

18-06-2018 09:37:04
Mandag morgen er det danske industrikabelselskab NKT røget ud af det fine selskab blandt eliteaktierne i det danske C25-indeks. Samtidig må selskabet se sin aktiekurs falde med 2,5 pct. til 191,10 kr. NKT kan nemlig skæve til den franske konkurrent Nexans, der venter en faldende indtjening i 2018, hvor driftsresultatet før af- og nedskrivninger ventes at lande på omkring 350 mio. euro, skriver Blo..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Nye C25-medlemmer, DSV og Vestas i fokus
2
Vestas/Sydbank: Regner med stærk afslutning på andet kvartal
3
KORR: Vestas: Modtager storordre på 442 MW i USA - GENT
4
Fingerprint Cards stiger en del efter chefers aktieopkøb
5
DSV/Morningstar: Sænker anbefalingen til "sælg"

Relaterede aktiekurser

Johnson & Johnson 121,32 -1,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. juni 2018 04:25:28
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180613.1 - EUROWEB3 - 2018-06-19 04:25:28 - 2018-06-19 04:25:28 - 1 - Website: OKAY